Abstract:To the Editor: The coagulation system is a complex regulatory system in the human body. In this case, the young patient had various vital thrombosis, including cerebral venous sinus thrombosis (CVST), coronary thrombosis, and left ventricular thrombus. However, the patient had neither hypercoagulable-related diseases nor risks nor coagulative or fibrinolytic protein deficiency.[1] Further genetic testing did not show the usual gene mutations relevant to coagulation dysfunction. We report such a patient with a slight elevation in coagulation FVIII activity and a rare FVIII gene duplication. The patient was a 24-year-old man with a history of CVST 3 years prior, and he was treated with warfarin (3 mg/day) for 1 year. Risk factors for atherosclerosis were initially absent, and he had no family history of coronary heart disease or recurrent thrombosis. The patient presented to the emergency room with intermittent chest pain for 11 days and oppressive ongoing chest pain for 11 h. The electrocardiogram showed ST-segment elevation in lead I, aVL, and V1–V6 [Figure 1A].Figure 1: Representative image of the patient. (A) The electrocardiogram of the patient, when he presented to the emergency room with oppressive ongoing chest pain, showed ST-segment elevation in lead I, aVL, and V1–V6. (B) The electrocardiogram of the patient, when his chest pain was relieved, showed ST-segment resolution. (C) Emergency coronary angiography showed that the LAD was incompletely obstructed with a thrombus. (D) Emergency coronary angiography revealed LAD reperfusion after thrombus aspiration therapy. (E) Cross-sectional OCT image of the culprit lesion. The arrowhead indicates the red thrombus, with high backscattering and high attenuation. The square frame indicates the normal artery wall. (F) The 3-layered architecture of the normal artery wall, comprising an intima that has high backscattering or is signal rich ( white arrow ), low backscattering, or signal-poor media ( yellow arrow ), and adventitia that frequently has high backscattering and is heterogeneous ( green arrow ). (G) Cross-sectional OCT image corresponding to the white arrowhead in the cross-sectional OCT image of the culprit lesion, showing that the area of the red thrombus was 5.58 mm2. LAD: Left anterior descending artery, OCT: Optical coherence tomography.His blood pressure was 145/78 mmHg, and his heart rate was 118 beats/min. No cardiac murmurs, crackles, or wheezes of lung bases were noted by auscultation. Emergency coronary angiography revealed that the left anterior descending (LAD) artery was incompletely obstructed with a thrombus that progressed distally [Figure 1C]. After thrombus aspiration therapy the coronary angiography showed LAD reperfusion [Figure 1D]. Optical coherence tomography (OCT) was performed after thrombus aspiration. The artery wall appeared to be normal, and the 3-layered architecture was clearly visible [Figure 1E and 1F] combined with a massive red thrombus [Figure 1G]. His echocardiography showed the decreased motion of the left ventricular apex. There was no mural thrombus or intracardiac shunt. A typical thrombophilia screen for activated protein C resistance, antithrombin III, protein S, anticardiolipin antibody, lupus anticoagulant, and fibrinogen showed that all levels were normal: antithrombin III was 95% (normal range 80%–120%), activated fibrinolysin was 95% (normal range 80%–150%), activated protein C was 91% (normal range 70%–140%), and protein S was 82% (normal range 63.5%–149%). Additionally, a hematological system panel genetic test was performed. The patient was administered a continuous infusion of platelet IIb/IIIa inhibitor (tirofiban 0.125 μg·kg−1·min−1) for 24 h followed by low-molecular-weight heparin (Clexane 6000 U every 12 h) for 4 days. His chest pain was relieved and the electrocardiogram showed ST-segment resolution [Figure 1B]. Based on secondary prevention, the patient was treated with dual antiplatelet drugs, an angiotensin-converting enzyme inhibitor (ACEI), a β receptor blocker, and statin; folate was added because of hyperhomocysteinemia. Anticoagulant therapy was not included given that no evidence of hypercoagulability was found. Four weeks after the MI, echocardiography showed left ventricular mural thrombus without any left ventricular wall motion abnormalities. The patient was then treated with warfarin (3 mg/day) in addition to dual antiplatelet therapy. Before warfarin was applied, his plasma levels of coagulation factor were assessed, with a slight elevation of coagulation FVIII activity to 166% (Normal range 100%–150%) noted; other coagulation factors were in the normal range. The hematological system panel test revealed a duplicate chrX: 153991029-154348425 region (including FVIII entire gene, GenBank: NM_000132.4). Two months later, echocardiography showed that the mural thrombus had disappeared. The patient was administered dual antiplatelet and warfarin therapy for 6 months, followed by aspirin and warfarin for 5 months. No recurrent thrombosis occurred. The patient had been diagnosed with CVST at the age of 21 years. CVST is a potentially devastating, though rare, thrombotic event, with an annual incidence of 3 to 4 cases per million individuals.[2] CVST occurs most often in young women, especially during pregnancy and the puerperium period, or in other acquired and congenital prothrombotic conditions such as infection.[3] The European Stroke Organization guidelines recommend using oral anticoagulants for 3 to 12 months after CVST. FVIII is a glycoprotein that plays a crucial role in the intrinsic pathway of blood coagulation. Elevations in FVIII levels are thought to be an independent risk factor for venous thrombosis. Elevated FVIII occurs frequently in patients with CVST and is a strong risk factor for this condition.[4] The relative contributions from genetic and inherited factors in the etiology of persistently elevated plasma FVIII levels remain unknown. Nevertheless, inherited factors may be important in at least some patients.[5] It remains unknown what gene mutations lead to FVIII elevation. Regarding the present case, the FVIII gene region duplication currently available in the Database of Genomic Variants does not cover the region we identified. Such changes might alter the production, activity, or metabolism of FVIII, affecting hemostasis and coagulation. Nonetheless, further mechanistic research is needed. Recent research found that JAK2V617F-positive essential thrombocythemia patients complicated with CVST were more likely to having thrombosis.[6] Therefore, genetic tests may contribute to risk stratification in CVST patients. This is a rare report of a patient who had a coronary thrombosis combined with CVST. Coagulopathy should be taken seriously, and genetic studies may be helpful. Declaration of patient consent The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed. Acknowledgments The authors thank Dr. Xiao-Hui Zhu and Dr. Rui Qiao for their kind assistance. Funding This work was supported by grants from the Major State Research Development Program of China (No. 2017YFC0908701) and the National Natural Science Foundation of China (No. 81400262). Conflicts of interest None.

Prothrombin gene G20210A mutation and elevated anticardiolipin antibodies in a patient with combined portal-mesenteric vein thrombosis

Portal vein thrombosis due to inherited combined deficiency of protein C and S in a young adult: A case report

Inherited antithrombin deficiency caused by a mutation in the SERPINC1 gene: A case report

Recurrent Venous and Arterial Thrombosis by Prothrombin P.r596q Heterozygous Mutation in a Chinese Patient: A Case Report and Literature Review

Portal Vein Thrombosis Can Aggravate Esophageal Variceal Bleeding After Endoscopic Variceal Ligation

Homozygous Factor V Leiden Complicated by Heparin-Induced Thrombocytopenia: A Case Report

A Rare Case of Pulmonary Embolism, Deep Vein Thrombosis, Bilateral Avascular Necrosis of the Femoral Head, and Miscarriage following COVID-19 in a Patient with Multiple Genetic Coagulation Factor Deficiency—A Case Report

Hereditary Thrombophilia: A Case of Subacute Pulmonary Embolism in a 68-Year-Old Female with a Mutation in the PROC Gene

Recurrent Vital Thrombotic Events in a Young Man with FVIII Gene Duplication

Catheter Intervention in a Patient with Intracranial Aneurysms and Glanzmann Thrombasthenia Caused by a Novel Homozygous Likely Pathogenic Variant in the ITGA2B Gene

Multiple Arterial and Venous Thromboembolism in a Male Patient with Hereditary Protein C Deficiency: A Case Report.

Hypercoagulability Existing in the Local Left Atrium of Patient with Mitral Stenosis

S4257 Portal Vein Thrombosis in the Setting of MTHFR Mutation Despite Full Anticoagulation on Apixaban (Eliquis)

S0981 Elevated Factor VIII Level is Associated with the Occurrence and Extent of Portal Vein Thrombosis in Cirrhosis

Isolated gastric varices associated with antiphospholipid syndrome and protein S deficiency: a case report and review of the literature

Multiple venous thrombosis caused by F9 gene duplication and treated with catheter-directed thrombolysis, AngioJet-assisted pharmaco-mechanical thromboectomy and manual aspiration thromboectomy

S5013 Splenic Artery and Portal Vein Thrombosis in the setting of MTHFR mutation despite Full Anticoagulation on Eliquis

Factor V Leiden Heterozygous: Complicated by Recurrent Venous Thromboembolism and Bilateral Pulmonary Embolism

Concurrent Cobalamin C and Plasminogen Deficiencies in a Patient with Chronic Thrombotic Microangiopathy

High Prevalence of F2 20210G > A in Splanchnic Vein Thrombosis and Cerebral Venous Sinus Thrombosis: A Retrospective Cohort Study of Patients with Thrombosis in Atypical Sites

Factor V haemostatic diathesis impairing thrombin activation, membrane binding and circulating antigen level due to a novel compound heterozygous mutation, Leu1821Ser and Gly2192Cys